Next Article in Journal
HDAC Inhibitor Abrogates LTA−Induced PAI-1 Expression in Pleural Mesothelial Cells and Attenuates Experimental Pleural Fibrosis
Next Article in Special Issue
Selective DNA Gyrase Inhibitors: Multi-Target in Silico Profiling with 3D-Pharmacophores
Previous Article in Journal
Discovery of Selective Inhibitor Leads by Targeting an Allosteric Site in Insulin-Regulated Aminopeptidase
Previous Article in Special Issue
Aryl Urea Based Scaffolds for Multitarget Drug Discovery in Anticancer Immunotherapies
Review

Dipeptidyl Peptidase (DPP)-IV Inhibitors with Antioxidant Potential Isolated from Natural Sources: A Novel Approach for the Management of Diabetes

by 1,*,†, 2,†, 3 and 2,4,*
1
Shri Vaishnav Institute of Science, Shri Vaishnav Vidyapeeth Vishwavidyalaya, Indore, Madhya Pradesh 453555, India
2
Department of Medical Biotechnology, Yeungnam University, Gyeongsan 38541, Korea
3
School of Life Sciences, Devi Ahilya University, Indore, Madhya Pradesh 452001, India
4
Research Institute of Cell Culture, Yeungnam University, Gyeongsan 38541, Korea
*
Authors to whom correspondence should be addressed.
Both the authors have contributed equally to the manuscript.
Academic Editor: Óscar López
Pharmaceuticals 2021, 14(6), 586; https://0-doi-org.brum.beds.ac.uk/10.3390/ph14060586
Received: 22 March 2021 / Revised: 8 June 2021 / Accepted: 13 June 2021 / Published: 18 June 2021
(This article belongs to the Special Issue Multitarget Drug Discovery and Pharmacology)
Type 2 diabetes mellitus (T2DM) is characterized by hyperglycemia that is predominantly caused by insulin resistance or impaired insulin secretion, along with disturbances in carbohydrate, fat and protein metabolism. Various therapeutic approaches have been used to treat diabetes, including improvement of insulin sensitivity, inhibition of gluconeogenesis, and decreasing glucose absorption from the intestines. Recently, a novel approach has emerged using dipeptidyl peptidase-IV (DPP-IV) inhibitors as a possible agent for the treatment of T2DM without producing any side effects, such as hypoglycemia and exhaustion of pancreatic β-cells. DPP-IV inhibitors improve hyperglycemic conditions by stabilizing the postprandial level of gut hormones such as glucagon-like peptide-1, and glucose-dependent insulinotropic polypeptides, which function as incretins to help upregulate insulin secretion and β-cell mass. In this review, we summarized DPP-IV inhibitors and their mechanism of inhibition, activities of those isolated from various natural sources, and their capacity to overcome oxidative stress in disease conditions. View Full-Text
Keywords: dipeptidyl peptidase-IV; glucagon-like peptide-1; hyperglycemia; incretin; antioxidant dipeptidyl peptidase-IV; glucagon-like peptide-1; hyperglycemia; incretin; antioxidant
Show Figures

Figure 1

MDPI and ACS Style

Singh, A.-K.; Yadav, D.; Sharma, N.; Jin, J.-O. Dipeptidyl Peptidase (DPP)-IV Inhibitors with Antioxidant Potential Isolated from Natural Sources: A Novel Approach for the Management of Diabetes. Pharmaceuticals 2021, 14, 586. https://0-doi-org.brum.beds.ac.uk/10.3390/ph14060586

AMA Style

Singh A-K, Yadav D, Sharma N, Jin J-O. Dipeptidyl Peptidase (DPP)-IV Inhibitors with Antioxidant Potential Isolated from Natural Sources: A Novel Approach for the Management of Diabetes. Pharmaceuticals. 2021; 14(6):586. https://0-doi-org.brum.beds.ac.uk/10.3390/ph14060586

Chicago/Turabian Style

Singh, Anand-Krishna, Dhananjay Yadav, Neha Sharma, and Jun-O Jin. 2021. "Dipeptidyl Peptidase (DPP)-IV Inhibitors with Antioxidant Potential Isolated from Natural Sources: A Novel Approach for the Management of Diabetes" Pharmaceuticals 14, no. 6: 586. https://0-doi-org.brum.beds.ac.uk/10.3390/ph14060586

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop